Semaglutide
Type 2 diabetes and weight managementGLP-1 peptide
NICENICE recommendations within defined criteriaNHSNHS access exists and is pathway constrained
Check current NICE source UK AND IRELAND · PROFESSIONAL PEPTIDE INTELLIGENCE
Know where every peptide really stands.
Search a molecule once. See authorisation, NICE position, NHS access, private-use context, evidence strength and market exposure as separate, source-linked answers.
25 priority records · field-level sources · verification dates shown
Can it be used and accessed?Licence, national assessment, health service and private context.What is coming next?Phase 3, filings and market readiness.What are patients asking about?Exposure signals, separated from evidence.
Independent professional intelligence. No medicine sales. No individual treatment advice. No dosing protocols.
MOLECULE ATLAS
Start with the peptides shaping the conversation.
A evidence
Semaglutide
GLP-1 receptor agonist peptide
UK authorised in specific products and indicationsConceptual molecular signatureA evidenceTirzepatide
GIP and GLP-1 receptor agonist peptide
UK authorised in specific products and indicationsConceptual molecular signatureA evidenceLiraglutide
GLP-1 receptor agonist peptide
UK authorised in specific products and indicationsConceptual molecular signatureA evidenceTesamorelin
GHRH analogue peptide
No UK marketing authorisation identified for the US indicationConceptual molecular signatureA evidenceBremelanotide
Melanocortin receptor agonist peptide
No equivalent UK marketing authorisation identifiedConceptual molecular signatureA evidenceElamipretide
Mitochondrial cardiolipin binding peptide
No UK marketing authorisation identifiedConceptual molecular signatureINSTITUTIONAL READINESS
NICE ready in method. Precise about status.
The evidence architecture is being developed with reference to the NICE Evidence Standards Framework. That is a preparation standard, not NICE assessment, endorsement or recommendation.
PEPTIDES FOR TOMORROW'S MEDICINE
Science moves through people before it moves through systems.
Discovery is only the beginning. Researchers, clinicians, pharmacists, regulators and evidence teams must be able to see what is established, what is emerging and where uncertainty remains. AI can compress the search and comparison work. It cannot turn preclinical evidence into a clinical recommendation.
01Discovery and evidence02Regulation and assessment03Responsible access
PHASE 3RetatrutideRegistered pivotal programme · sponsor announced filing plan
LAWFUL USEUK precedentsProduct, indication and access distinctions
FDA REVIEW7 peptides503A nominations reviewed in July 2026, not drug approvals
THE CORE ASSET
One atlas. Eight questions kept distinct.
Government sources answer individual regulatory questions. This view joins the sequence: FDA → MHRA → NICE → NHS access → private context → evidence → exposure → what comes next.
authorised comparatorlate-stage pipelinereview or surveillance25 records · each field independently sourced
Molecule results
FDA approved comparator10/10 UK readiness
Semaglutide
GLP-1 receptor agonist peptide
Type 2 diabetes · obesity · cardiometabolic disease
- MHRA / UK licence
- UK authorised in specific products and indications
- NICE
- NICE recommendations exist for defined diabetes and obesity uses
- Evidence
- AAuthorised medicine with large Phase 3 and post marketing evidence base
- Exposure
- Very high
FDA approved comparator10/10 UK readiness
Tirzepatide
GIP and GLP-1 receptor agonist peptide
Type 2 diabetes · chronic weight management
- MHRA / UK licence
- UK authorised in specific products and indications
- NICE
- NICE TA1026 recommends tirzepatide with eligibility criteria
- Evidence
- AAuthorised medicine with pivotal obesity and diabetes evidence
- Exposure
- Very high
FDA approved comparator10/10 UK readiness
Liraglutide
GLP-1 receptor agonist peptide
Type 2 diabetes · obesity
- MHRA / UK licence
- UK authorised in specific products and indications
- NICE
- NICE TA664 recommends liraglutide for a defined obesity pathway
- Evidence
- ALong standing controlled evidence and post marketing use
- Exposure
- High
FDA approved comparator5/10 UK readiness
Tesamorelin
GHRH analogue peptide
Excess abdominal fat in HIV associated lipodystrophy
- MHRA / UK licence
- No UK marketing authorisation identified for the US indication
- NICE
- No NICE recommendation identified
- Evidence
- AAuthorised US evidence for a narrow indication only
- Exposure
- High research market
FDA approved comparator4/10 UK readiness
Bremelanotide
Melanocortin receptor agonist peptide
Acquired generalised hypoactive sexual desire disorder in premenopausal women
- MHRA / UK licence
- No equivalent UK marketing authorisation identified
- NICE
- No NICE recommendation identified
- Evidence
- AControlled evidence for a specific labelled US use
- Exposure
- Moderate research market
FDA approved comparator4/10 UK readiness
Elamipretide
Mitochondrial cardiolipin binding peptide
Barth syndrome
- MHRA / UK licence
- No UK marketing authorisation identified
- NICE
- No NICE recommendation identified
- Evidence
- AAccelerated approval with a confirmatory study requirement
- Exposure
- Emerging
FDA approved comparator8/10 UK readiness
Setmelanotide
MC4 receptor agonist peptide
Defined monogenic and syndromic obesity
- MHRA / UK licence
- UK authorised for defined genetic obesity indications
- NICE
- NICE highly specialised recommendations exist for defined populations
- Evidence
- AAuthorised evidence in genetically defined obesity populations
- Exposure
- Specialist
FDA approved comparator9/10 UK readiness
Teduglutide
GLP-2 analogue peptide
Short bowel syndrome
- MHRA / UK licence
- UK authorised for a specific product and indication
- NICE
- NICE TA804 recommends teduglutide for short bowel syndrome
- Evidence
- AAuthorised evidence in short bowel syndrome
- Exposure
- Specialist
Late stage pipeline6/10 UK readiness
Retatrutide
GIP · GLP-1 · glucagon triple agonist peptide
Obesity · type 2 diabetes · OSA · knee osteoarthritis · cardiometabolic disease
- MHRA / UK licence
- Investigational; no UK marketing authorisation
- NICE
- No NICE recommendation identified
- Evidence
- BPivotal Phase 3 programme with sponsor reported topline results
- Exposure
- Very high grey market interest
Late stage pipeline5/10 UK readiness
Cagrilintide
Long acting amylin analogue peptide
Obesity · appetite regulation
- MHRA / UK licence
- Investigational; no UK marketing authorisation
- NICE
- No NICE recommendation identified
- Evidence
- BRegistered late stage development programme
- Exposure
- High research market interest
Late stage pipeline4/10 UK readiness
Zenagamtide
Unimolecular GLP-1 and amylin receptor agonist peptide
Obesity · type 2 diabetes
- MHRA / UK licence
- Investigational; no UK marketing authorisation
- NICE
- No NICE recommendation identified
- Evidence
- BPhase 2 signal with registered Phase 3 development
- Exposure
- Emerging
Late stage pipeline4/10 UK readiness
Pemvidutide
GLP-1 and glucagon dual receptor agonist peptide
MASH · metabolic disease
- MHRA / UK licence
- Investigational; no UK marketing authorisation
- NICE
- No NICE recommendation identified
- Evidence
- BPositive Phase 2b results with registered Phase 3 development
- Exposure
- Emerging
Late stage pipeline4/10 UK readiness
Survodutide
GLP-1 and glucagon dual receptor agonist peptide
Obesity · MASH · cardiometabolic risk
- MHRA / UK licence
- Investigational; no UK marketing authorisation
- NICE
- No NICE recommendation identified
- Evidence
- BRegistered Phase 3 development across obesity and MASH
- Exposure
- Emerging
FDA 2026 compounding review1/10 UK readiness
BPC 157
Synthetic pentadecapeptide
FDA evaluated a nomination associated with ulcerative colitis
- MHRA / UK licence
- No UK marketing authorisation identified
- NICE
- No NICE recommendation identified
- Evidence
- CLimited human evidence relative to extensive online claims
- Exposure
- Very high research market
FDA 2026 compounding review1/10 UK readiness
KPV
Alpha MSH derived tripeptide
FDA evaluated wound healing and inflammatory condition nominations
- MHRA / UK licence
- No UK marketing authorisation identified
- NICE
- No NICE recommendation identified
- Evidence
- CPreclinical and limited human evidence
- Exposure
- Growing research market
FDA 2026 compounding review1/10 UK readiness
TB 500
Thymosin beta-4-related peptide
FDA evaluated a wound healing nomination
- MHRA / UK licence
- No UK marketing authorisation identified
- NICE
- No NICE recommendation identified
- Evidence
- CMarketed combination use substantially exceeds controlled human evidence
- Exposure
- Very high research market
FDA 2026 compounding review1/10 UK readiness
MOTS-c
Mitochondrial derived peptide
FDA evaluated obesity and osteoporosis nominations
- MHRA / UK licence
- No UK marketing authorisation identified
- NICE
- No NICE recommendation identified
- Evidence
- CMechanistic and early human interest without authorised therapeutic use
- Exposure
- High research market
FDA 2026 compounding review1/10 UK readiness
Emideltide / DSIP
Delta sleep inducing peptide
FDA evaluated nominations associated with opioid withdrawal, insomnia and narcolepsy
- MHRA / UK licence
- No UK marketing authorisation identified
- NICE
- No NICE recommendation identified
- Evidence
- CLimited clinical evidence
- Exposure
- Moderate research market
FDA 2026 compounding review1/10 UK readiness
Semax
ACTH fragment analogue peptide
FDA evaluated nominations associated with cerebral ischaemia, migraine and trigeminal neuralgia
- MHRA / UK licence
- No UK marketing authorisation identified
- NICE
- No NICE recommendation identified
- Evidence
- CInternational and limited evidence is not equivalent to US or UK authorisation
- Exposure
- High nootropic market
FDA 2026 compounding review1/10 UK readiness
Epitalon
Tetrapeptide
FDA evaluated an insomnia nomination
- MHRA / UK licence
- No UK marketing authorisation identified
- NICE
- No NICE recommendation identified
- Evidence
- CLimited modern human evidence relative to longevity claims
- Exposure
- High longevity market
FDA 2027 compounding review1/10 UK readiness
LL-37
Human cathelicidin antimicrobial peptide
Immune and antimicrobial research
- MHRA / UK licence
- No UK marketing authorisation identified
- NICE
- No NICE recommendation identified
- Evidence
- DResearch interest with material safety and formulation questions
- Exposure
- Emerging
FDA 2027 compounding review1/10 UK readiness
GHK-Cu
Copper binding tripeptide complex
Tissue and dermal research · cosmetic context
- MHRA / UK licence
- No UK injectable marketing authorisation identified for wellness use
- NICE
- No NICE recommendation identified for injectable wellness use
- Evidence
- DCosmetic and biological literature does not validate injectable blend claims
- Exposure
- Very high
FDA 2027 compounding review0/10 UK readiness
Dihexa acetate
Experimental peptide derived compound
Cognitive and neurotrophic research
- MHRA / UK licence
- No UK marketing authorisation identified
- NICE
- No NICE recommendation identified
- Evidence
- DPredominantly preclinical interest
- Exposure
- Emerging nootropic market
FDA 2027 compounding review0/10 UK readiness
Melanotan II
Melanocortin analogue peptide
Pigmentation and melanocortin research
- MHRA / UK licence
- No UK marketing authorisation identified
- NICE
- No NICE recommendation identified
- Evidence
- DNo authorised therapeutic tanning use and material safety concern
- Exposure
- Very high grey market
FDA 2027 compounding review0/10 UK readiness
PEG-MGF
Pegylated mechano-growth factor related peptide
Muscle and recovery research market
- MHRA / UK licence
- No UK marketing authorisation identified
- NICE
- No NICE recommendation identified
- Evidence
- DLimited evidence and substantial extrapolation from growth factor biology
- Exposure
- Bodybuilding research market
RECORD STANDARDField level source links
VERSION CONTROLVerified date and record version
EVIDENCE DISCIPLINEFact separated from signal
CORRECTIONSMaterial changes logged
FIRST MARKET SCOPE
National access is not one UK field.
The launch model separates authorisation from country specific assessment, reimbursement, commissioning and implementation.
Compare access routesLAWFUL UK CLINICAL USE NOW
The peptide future has already started.
The useful starting point is what can lawfully be prescribed or supplied in the UK now, for which indication, under what governance, and whether NICE and the NHS support access.
Tirzepatide
Type 2 diabetes and weight managementGIP / GLP-1 peptide
NICENICE TA1026 recommendationNHSPhased NHS implementation and prioritisation
Check current NICE source Liraglutide
Type 2 diabetes and weight managementGLP-1 peptide
NICENICE TA664 recommendation for a defined pathwayNHSSpecialist NHS access within criteria
Check current NICE source Setmelanotide
Defined genetic obesity syndromesMC4 receptor agonist peptide
NICENICE highly specialised recommendationsNHSSpecialist NHS access for eligible populations
Check current NICE source Teduglutide
Short bowel syndromeGLP-2 analogue peptide
NICENICE TA804 recommendationNHSSpecialist access subject to criteria and commissioning
Check current NICE source Abaloparatide
Osteoporosis after menopause at very high fracture riskPTHrP analogue peptide
NICENICE TA991 recommendationNHSNHS access within the recommendation and commercial arrangement
Check current NICE source Somatropin / somapacitan
Diagnosed growth hormone deficiency and defined growth disordersGrowth hormone therapeutics
NICENICE recommendations exist for defined populationsNHSSpecialist endocrine and shared care pathways
Check current NICE source Teriparatide
Selected osteoporosis populationsPTH analogue peptide
NICENICE recommendation for defined secondary prevention populationsNHSAccess within applicable osteoporosis pathways
Check current NICE source EXPOSURE SURVEILLANCE
Recognise the pattern. Do not validate the stack.
Observed combinations are market and clinic signals, not recommendations. Component evidence does not establish the safety, quality or efficacy of a premixed product.
BPC 157 + TB-500
A common research market pairing. No approved combination product and no controlled combination evidence establishing the marketed use.
High exposure · evidence gapBPC 157 + TB-500 + GHK-Cu + KPV
Observed as KLOW style market architecture. Four components compound questions of identity, attribution, stability and sterility.
High complexity · high governance needCJC-1295 no DAC + ipamorelin
A frequently described clinic and research pairing. Component rationale is not validation of a fixed premixed formulation.
Established market patternINVITE ONLY BETA · FIRST COHORT
Challenge the answer. Check the source. Measure the time saved.
We are inviting a small group of clinicians, pharmacists, governance professionals and life sciences teams to test the platform against real professional questions before wider launch.